Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
PITTSBURGH - Predictive Oncology Inc. (NASDAQ: POAI), an AI-driven drug discovery company, announced today that the Delaware Court of Chancery has set a trial date for its legal dispute with Renovaro, Inc. The trial is scheduled for November 12-13, 2025, following the court’s refusal to expedite Renovaro’s request for a two-day trial in July. The company’s stock, currently trading at $0.98, has seen a significant 25% gain over the past six months despite recent volatility. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation.
The court’s decision to reject the expedited trial was based on Renovaro’s delay in bringing its action against Predictive Oncology. In response to the allegations made by Renovaro, Predictive Oncology has stated that it fully intends to protect its rights and defend against what it describes as baseless claims.
Predictive Oncology specializes in the use of artificial intelligence (AI) and machine learning for early drug discovery, focusing on cancer treatment. The company claims that its AI platform, PEDAL, can predict with 92% accuracy how a tumor sample will respond to a specific drug compound. This technology is intended to guide the selection of drug and tumor type combinations for further in-vitro testing. InvestingPro data reveals the company maintains a solid gross profit margin of 51%, though it faces challenges with cash burn. The platform’s Financial Health Score indicates a weak overall position, suggesting careful monitoring is needed.
The company also maintains a biobank with over 150,000 assay-capable heterogeneous human tumor samples, which it offers to both academic and industry partners as part of its drug discovery solutions. Predictive Oncology operates a wholly owned CLIA laboratory facility and is headquartered in Pittsburgh, PA.
This news comes as part of a press release statement issued by Predictive Oncology. The company has cautioned that certain statements in the press release are forward-looking and subject to risks, uncertainties, and assumptions. Analysts tracked by InvestingPro project revenue growth of 4.75% for FY2025, with 8 additional exclusive ProTips available to subscribers. For comprehensive analysis, including detailed financial metrics and expert insights, investors can access the full Pro Research Report, available for over 1,400 US stocks on the platform. Predictive Oncology has also indicated that it does not guarantee future performance will align with current expectations or projections.
Investors and interested parties are advised to consider the company’s SEC filings for a more comprehensive understanding of the risks involved. Predictive Oncology has not provided further details on the nature of the dispute with Renovaro, focusing instead on the upcoming court proceedings.
In other recent news, Predictive Oncology has made a notable advancement in its AI-enabled drug discovery capabilities, developing predictive tumor response models for 21 molecules without prior response data. This achievement highlights the company’s integration of AI and machine learning to expedite early-stage drug discovery. Meanwhile, Renovaro Biosciences faces a setback as Predictive Oncology terminated their planned merger. Renovaro claims Predictive Oncology breached the binding agreements and has set an April 10 deadline for compliance, threatening legal action if obligations are not met. The merger was intended to consolidate AI/ML platform technologies and expand operations in Europe and the United States. Predictive Oncology’s recent breakthroughs reflect a broader industry trend towards integrating genomics and AI in precision medicine. Renovaro continues to focus on its AI and biotechnology platforms to advance personalized medicine. Both companies are navigating significant developments impacting their strategic directions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.